Top Markets
#1 Purr Purr +57.78%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +34.50%
#4 Kinetiq Kinetiq +25.62%
#5 ApeX ApeX +23.09%
#6 Non-Playable Coin Non-Playable Coin +20.44%
#7 OriginTrail OriginTrail +19.45%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.44%
#9 龙虾 (Lobster) 龙虾 (Lobster) +18.17%
#10 Zora Zora +18.01%
Coin of the day
Purr Purr
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Cumberland Pharmaceuticals Inc. Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc.

CPIX
Classement en actions #21215
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical... Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Prix de l'action
$7.51
Dernière synchronisation: 2026-08-21
Capitalisation boursière
$112.52M
Changement (1 jour)
0.13%
Changement (1 an)
128.27%
Pays
US
Échange Cumberland Pharmaceuticals Inc. (CPIX)

Catégorie

Healthcare
Nombre d'actions en circulation pour Cumberland Pharmaceuticals Inc. (CPIX)
Nombre d'actions en circulation au August 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Cumberland Pharmaceuticals Inc., le nombre actuel d'actions en circulation est de 0. À la fin de August 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Cumberland Pharmaceuticals Inc. (CPIX) de 2026 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
Pas assez de données pour les dates fournies.
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 2.40B -
IN